GCC AI-based Clinical Trials Solution Provider Market (Clinical Trial Phase - Phase-I, Phase-II, and Phase-III; Therapeutic Application - Cancer, Cardiovascular Disease, Neurological Disease, Metabolic Disease, Infectious Disease, and Others): GCC Industry Analysis, Trends, Size, Share and Forecasts to 2028

GCC AI-based Clinical Trials Solution Provider Market (Clinical Trial Phase - Phase-I, Phase-II, and Phase-III; Therapeutic Application - Cancer, Cardiovascular Disease, Neurological Disease, Metabolic Disease, Infectious Disease, and Others): GCC Industry Analysis, Trends, Size, Share and Forecasts to 2028

Report Code: GCC042 Region: GCC Published: May, 2022

A recent report ongoing study by Infinium Global Research on the AI-based clinical trials solution provider market provides an in-depth analysis of segments and sub-segments in the GCC as well as regional AI-based clinical trials solution provider market. The study also highlights the impact of drivers, restraints, and macro indicators on the GCC and regional AI-based clinical trials solution provider market over the short term as well as long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of the GCC AI-based clinical trials solution provider market. According to the report, the GCC AI-based clinical trials solution provider market is projected to grow at a significant CAGR over the forecast period of 2022-2028.

Market Insight

Artificial intelligence (AI) has propelled many industries toward a new, highly functional, and powerful state. Now they are starting to make their way into the clinical research realm advancing clinical operations, as well as data management. Clinical trials are a crucial requirement, enabling both innovators and regulators to assess the efficacy of a candidate drug and establish whether it is safe for use in humans. It is estimated that nearly 50% of the total time and capital expenditure during the drug development process, is on conducting clinical research. Artificial intelligence has the potential to shorten clinical trial cycle durations while also enhancing productivity and clinical development outcomes. However, AI adoption in the actual clinical trial process is still in its early stages.

The Covid-19 pandemic has glimmered the adoption of technologies that can improve the efficiency and cost of the traditional clinical trial process. To keep people healthier and safer in the future, we will have to become increasingly dependent on quick-moving and highly effective trials. The sudden outbreak of the Covid-19 pandemic has initiated an augmentation in the deployment of AI-sourced technologies. Rising acceptance of scientifically highly developed results, intended for the drug invention, and improvement along with the scrutiny of enlisted information of the patients are a few factors, accountable for the rise in the infiltration of AI-sourced medicine development as well as clinical trial results, throughout the Covid-19 pandemic.

The rising number of clinical research and studies, increasing government and private investments in healthcare infrastructure development, and the introduction of novel AI-based technologies in the healthcare sector are important factors driving the market revenue growth. The adoption of AI-based platforms and technologies by pharmaceutical companies and academia, along with the increasing adoption of artificial intelligence (AI) are the factors driving the market growth. Due to the possibility of a defective diagnosis, the market is expected to hinder its growth in the forecasting years. Technological advancements and innovations in AI-based clinical trials are providing lucrative opportunities for its market in the upcoming years.

UAE region to dominate in AI-based clinical trials solution provider market. The healthcare sector’s imperative to transform has gained momentum during the pandemic when delivering connected, integrated, and seamless care to patients, those who are elderly or suffering from chronic conditions, which led to an urgent need to disrupt and reimagine legacy systems and care delivery pathways. Abu Dhabi-based G42 Healthcare has invested in a genomic sequencing program to support improved and early diagnosis of markers for cancer and other chronic conditions, and in the future to support longevity programs.

Segment Covered

The report on GCC AI-based clinical trials solution provider market covers segments such as the clinical trial phase and therapeutic application. On the basis of the clinical trial phase, the sub-markets include phase -I, phase II, and phase III. On the basis of therapeutic application, the sub-markets include cancer, cardiovascular disease, neurological disease, metabolic disease, infectious disease, and others.

GCC AI-based Clinical Trials Solution Provider Market

Companies Profiled:

The report provides profiles of the companies in the market such as Unlearn AI Inc, Saama Technologies, Inc, Deep 6 AI, Innoplexus, Symphony AI, Mendel.ai, AiCure, and Ardigen, BioSymetrics, and GNS Healthcare.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the GCC AI-based clinical trials solution provider market. Moreover, the study highlights current market trends and provides forecasts for 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


CHOOSE LICENCE TYPE

Please Choose One of them.


$3735.75

$6396.00
© 2022. Infinium Global Research LLP. All Rights Reserved.